Document Detail


Thrombin and protease-activated receptors (PARs) in atherothrombosis.
MedLine Citation:
PMID:  18278179     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thrombin is a multifunctional serine protease generated at the site of vascular injury that transforms fibrinogen into fibrin, activates blood platelets and elicits multiple effects on a variety of cell types including endothelial cells, vascular smooth muscle cells (VSMC), monocytes, T lymphocytes and fibroblasts. Cellular effects of thrombin are mediated by protease-activated receptors (PARs), members of the G protein-coupled receptors that carry their own ligand which remains cryptic until unmasked by proteolytic cleavage. Thrombin signalling in platelets contributes to haemostasis and thrombosis. In normal arteries PARs are mainly expressed in endothelial cells, while their expression in VSMC is limited. Endothelial PARs participate in the regulation of vascular tone, vascular permeability and endothelial secretory activity while in VSMC they mediate contraction, migration, proliferation, hypertrophy and production of extracellular matrix. PARs contribute to the pro-inflammatory phenotype observed in endothelial dysfunction and their up-regulation in VSMC seems to be a key element in the pathogenesis of atherosclerosis and restenosis. In the last years a myriad of studies have emphasized the critical role of PAR signalling in thrombin mediated effects in haemostasis, inflammation, cancer and embryonic development. Lately, PARs have become a therapeutic target to inhibit platelet aggregation and thrombosis. Early data from a clinical trial (TRA-PCI) to evaluate safety and efficacy of a potent new oral thrombin receptor antagonist (TRA) have promisingly indicated that overall TRA treatment reduces adverse event rates without an increase in bleeding risk. In this paper we review cellular responses triggered by thrombin and their implication in vascular pathophysiology.
Authors:
Lluis Martorell; José Martínez-González; Cristina Rodríguez; Maurizio Gentile; Olivier Calvayrac; Lina Badimon
Related Documents :
6753229 - Thrombin inhibition and thrombin generation by cultured aortic endothelial and smooth m...
19265029 - Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombo...
15819679 - Stored platelets contain residual amounts of tissue factor: evidence from studies on pl...
14577849 - Activated protein c signals through the thrombin receptor par1 in endothelial cells.
8547149 - Induction of tissue factor expression in human monocyte/endothelium cocultures.
9495249 - Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase p...
14517449 - Endometrial angiogenesis.
9250159 - Expression of p-cadherin identifies prostate-specific-antigen-negative cells in epithel...
9861439 - Erythrocyte antioxidant systems protect cultured endothelial cells against oxidant damage.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  99     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-18     Completed Date:  2008-04-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  305-15     Citation Subset:  IM    
Affiliation:
Centro de Investigación Cardiovascular, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret #167, 08025 Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atherosclerosis / blood,  drug therapy,  metabolism*,  physiopathology
Blood Coagulation
Blood Platelets / metabolism
Constriction, Pathologic
Endothelial Cells / metabolism
Hemorrhage / blood,  metabolism
Humans
Myocytes, Smooth Muscle / metabolism
Neovascularization, Physiologic
Platelet Aggregation Inhibitors / pharmacology,  therapeutic use
Receptors, Proteinase-Activated / antagonists & inhibitors,  blood,  metabolism*
Recurrence
Signal Transduction* / drug effects
Thrombin / metabolism*
Thrombosis / blood,  drug therapy,  metabolism*,  physiopathology
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Receptors, Proteinase-Activated; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk ...
Next Document:  The antigenic binding sites of autoantibodies to factor XII in patients with recurrent pregnancy los...